Form 4: Abbott Laboratories Director Patricia Paola Gonzalez Reports Acquisition of Stock Equivalent Units

Director Patricia Paola Gonzalez reports acquisition of 317 stock equivalent units in Abbott Laboratories through director fees credited to a grantor trust.

Summary

• On June 30, 2024, Patricia Paola Gonzalez, a director of Abbott Laboratories, acquired 317 stock equivalent units.
• These units were obtained through director fees credited to a stock equivalent unit account under a grantor trust.
• The price of the stock equivalent units was $103.91.
• Following the transaction, Gonzalez beneficially owns 3,509 stock equivalent units.
• These units earn the same return as if the fees were invested in Abbott shares and are generally paid out in cash at age 65 or upon retirement from the board.
• The balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. It reflects a standard transaction related to director compensation, indicating alignment with shareholder interests. There are no explicit negative implications.

Positives

• The acquisition of stock equivalent units demonstrates the director's continued investment in Abbott Laboratories.
• The dividend reinvestment feature further increases the director's stake in the company.

Future Outlook

The stock equivalent units are generally paid out in cash at age 65 or upon retirement from the board.

Industry Context

Directors often receive stock options or equivalent units as part of their compensation, aligning their interests with those of shareholders. This transaction reflects a standard practice in corporate governance.

Comparison to Industry Standards

• Director compensation packages often include stock options or restricted stock units to align their interests with shareholders, similar to practices at companies like Johnson & Johnson and Pfizer.
• The use of grantor trusts for managing director fees is a common practice to defer income and manage tax implications, comparable to arrangements seen at other large pharmaceutical companies.

Key Dates